IQVIA (NYSE:IQV) Releases FY 2026 Earnings Guidance

IQVIA (NYSE:IQV) issued an update on its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 12.800-13.000 for the period, compared to the consensus estimate of 12.570. The company issued revenue guidance of $17.3 billion-$17.5 billion, compared to the consensus revenue estimate of $17.3 billion.

IQVIA Trading Up 2.4%

IQV traded up $5.75 on Wednesday, hitting $248.69. 339,599 shares of the company were exchanged, compared to its average volume of 1,805,368. The stock has a market capitalization of $41.51 billion, a PE ratio of 30.84, a price-to-earnings-growth ratio of 1.91 and a beta of 1.20. IQVIA has a 12 month low of $154.50 and a 12 month high of $251.36. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The firm has a fifty day simple moving average of $190.47 and a two-hundred day simple moving average of $186.86.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same period in the prior year, the business earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Sell-side analysts expect that IQVIA will post 11.57 earnings per share for the current year.

IQVIA announced that its Board of Directors has initiated a share repurchase plan on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. HSBC reissued a “buy” rating and set a $240.00 target price on shares of IQVIA in a research note on Monday, July 6th. Barclays restated an “overweight” rating on shares of IQVIA in a research report on Tuesday. Robert W. Baird raised their target price on shares of IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday. Morgan Stanley restated an “equal weight” rating and issued a $200.00 price target (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a research report on Thursday, July 9th. Thirteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $229.12.

Key Headlines Impacting IQVIA

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Second-quarter earnings and revenue beat expectations. IQVIA reported adjusted EPS of $3.15, above the $3.02–$3.03 consensus range, while revenue reached $4.37 billion versus approximately $4.30 billion expected. Revenue grew 8.7% year over year, and EPS increased from $2.81 in the prior-year quarter. IQVIA Reports Second-Quarter 2026 Results
• Positive Sentiment: Management raised its 2026 earnings guidance. IQVIA now expects full-year EPS of $12.80 to $13.00, above the prior consensus estimate of $12.57. Revenue guidance was set at $17.3 billion to $17.5 billion, broadly in line with expectations. IQVIA stock gains on Q2 beat and guidance hike
• Positive Sentiment: Bookings and backlog point to sustained demand. Record research-and-development bookings, broad-based growth and a ballooning backlog supported the improved outlook, suggesting stronger future revenue visibility for IQVIA’s clinical-research business. IQV Q2 earnings beat estimates on R&D bookings
• Positive Sentiment: Analyst sentiment improved. Robert W. Baird raised its price target from $252 to $287 and maintained an “Outperform” rating, indicating potential additional upside based on the stronger earnings and outlook.
• Neutral Sentiment: Valuation is receiving greater investor attention. With IQVIA trading near its 12-month high and at a reported price-to-earnings ratio of about 30, the earnings beat and guidance increase must continue to justify the stock’s higher valuation. IQVIA Holdings earnings beat keeps fair value in focus

Institutional Trading of IQVIA

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IQV. Brighton Jones LLC grew its holdings in shares of IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after buying an additional 2,537 shares during the last quarter. Sivia Capital Partners LLC purchased a new stake in shares of IQVIA during the second quarter worth approximately $514,000. Wealth Watch Advisors INC lifted its position in IQVIA by 26.3% in the fourth quarter. Wealth Watch Advisors INC now owns 495 shares of the medical research company’s stock valued at $112,000 after purchasing an additional 103 shares during the period. Transamerica Financial Advisors LLC boosted its position in shares of IQVIA by 16.7% during the 4th quarter. Transamerica Financial Advisors LLC now owns 495 shares of the medical research company’s stock worth $112,000 after purchasing an additional 71 shares in the last quarter. Finally, Group One Trading LLC lifted its position in shares of IQVIA by 256.7% during the 4th quarter. Group One Trading LLC now owns 470 shares of the medical research company’s stock valued at $106,000 after acquiring an additional 770 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.